Table 1.
Clinical and laboratory characteristics of the study subjects
| Characteristics | HCV–HCC patients (n = 40) |
Controls (n = 40) |
|---|---|---|
| Age (years) | 63.7 ± 1 | 58 ± 2 |
| Sex | ||
| Males | 36 (90%) | 34 (85%) |
| Females | 4 (10%) | 6 (15%) |
| ALT (U/L) | 45.5 ± 7 | 10.3 ± 0.3 |
| AST (U/L) | 94 ± 14 | 11 ± 0.5 |
| Albumin (gm/L) | 30.7 ± 1 | 40.3 ± 0.1 |
| Total protein (gm/L) | 69.9 ± 2 | 70 ± 3 |
| Total bilirubin (mg/dL) | 23.5 ± 2 | 0.8 ± 0.04 |
| Prothrombin time (seconds) | 13.9 ± 0.3 | 12 ± 0.3 |
| INR | 1.2 ± 0.03 | 1 ± 0.01 |
| Hemoglobin (g/dl) | 10.9 ± 0.4 | 13.2 ± 0.3 |
| WBCs (109/L) | 7.2 ± 0.5 | 8.2 ± 0.3 |
| Platelet count | 162.2 ± 14 | 254.5 ± 11 |
| Liver cirrhosis | 40 (100%) | – |
| Child–Pugh score | 7.1 ± 0.3 | – |
| Ascites | ||
| No | 23 (57.5%) | – |
| Mild | 3 (7.5%) | |
| Moderate | 14 (35%) | |
| Hepatic encephalopathy | 8 (20%) | – |
| Splenomegaly | 20 (50%) | – |
| HFL | ||
| 1 | 14 (35%) | – |
| 2 | 8 (20%) | |
| 3 | 18 (45%) | |
| Portal vein thrombosis | 31 (77.5%) | – |
| Alpha-fetoprotein (ng/ml) | 12,661.8 ± 11,036.6 | – |
| Patients on Daclatasvir /sofosbuvir treatment regimen | 9 (22.5%) | – |
| Deaths | 6 (15%) | – |
HCV–HCC hepatitis C related hepatocellular carcinoma, ALT alanine aminotransferase, AST aspartate aminotransferase, INR international normalized ratio, MCV mean corpuscular volume, MCHC mean corpuscular hemoglobin concentration, WBCs white blood cells, HFL hepatic focal lesions
Data expressed as mean ± SE or number (percentage), accordingly